Current objectives regarding treatment of acute myeloid leukemia (AML) include achieving complete remission (CR) by clinicopathological criteria followed by interrogation for the presence of minimal/measurable residual disease (MRD) by molecular genetic and/or flow cytometric techniques. Although advances in molecular genetic technologies have enabled highly sensitive detection of AML-associated mutations and translocations, determination of MRD is complicated by the fact that many treated patients have persistent clonal hematopoiesis (CH) that may not reflect residual AML. CH detected in AML patients in CR includes true residual or early recurrent AML, myelodysplastic syndrome or CH that is ancestral to the AML, and independent or newly emerging clones of uncertain leukemogenic potential. Although the presence of AML-related mutations has been shown to be a harbinger of relapse in multiple studies, the significance of other types of CH is less well understood. In patients who undergo allogeneic hematopoietic cell transplantation (HCT), post-HCT clones can be donor-derived and in some cases engender a new myeloid neoplasm that is clonally unrelated to the recipient's original AML. In this article, we discuss the spectrum of CH that can be detected in treated AML patients, propose terminology to standardize nomenclature in this setting, and review clinical data and areas of uncertainty among the various types of posttreatment hematopoietic clones.
© 2020 by The American Society of Hematology.
Conflict of interest statement
Conflict-of-interest disclosure: B.L.E. has received research funding from Celgene and Deerfield; has received consulting fees from GRAIL; and serves on the scientific advisory boards for, and holds equity in, Skyhawk Therapeutics and Exo Therapeutics. T.G. has received research funding from Janssen and Calico. The remaining authors declare no competing financial interests.
Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.Leukemia. 2017 Jun;31(6):1286-1295. doi: 10.1038/leu.2016.345. Epub 2016 Nov 24. Leukemia. 2017. PMID: 27881874
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.Biol Blood Marrow Transplant. 2014 Apr;20(4):549-55. doi: 10.1016/j.bbmt.2014.01.009. Epub 2014 Jan 16. Biol Blood Marrow Transplant. 2014. PMID: 24440648 Free PMC article. Clinical Trial.
Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.Best Pract Res Clin Haematol. 2013 Sep;26(3):279-84. doi: 10.1016/j.beha.2013.10.008. Epub 2013 Oct 16. Best Pract Res Clin Haematol. 2013. PMID: 24309531 Review.
Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant. 2016 Nov;22(11):1974-1982. doi: 10.1016/j.bbmt.2016.08.014. Epub 2016 Aug 17. Biol Blood Marrow Transplant. 2016. PMID: 27544285 Free PMC article.
Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.Int J Mol Sci. 2018 Nov 6;19(11):3492. doi: 10.3390/ijms19113492. Int J Mol Sci. 2018. PMID: 30404199 Free PMC article. Review.